BRPI0907371A2 - derivados de insulina com um perfil de tempo-ação muito retardado - Google Patents

derivados de insulina com um perfil de tempo-ação muito retardado

Info

Publication number
BRPI0907371A2
BRPI0907371A2 BRPI0907371A BRPI0907371A BRPI0907371A2 BR PI0907371 A2 BRPI0907371 A2 BR PI0907371A2 BR PI0907371 A BRPI0907371 A BR PI0907371A BR PI0907371 A BRPI0907371 A BR PI0907371A BR PI0907371 A2 BRPI0907371 A2 BR PI0907371A2
Authority
BR
Brazil
Prior art keywords
delayed time
insulin derivatives
action profile
profile
action
Prior art date
Application number
BRPI0907371A
Other languages
English (en)
Inventor
Georg Tschank
Gerhard Seipke
Günter Müller
Mark Sommerfeld
Norbert Tennagels
Paul Habermann
Roland Kurrle
Ulrich Werner
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40568276&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0907371(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DE200810003568 external-priority patent/DE102008003568A1/de
Priority claimed from DE200810025008 external-priority patent/DE102008025008A1/de
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of BRPI0907371A2 publication Critical patent/BRPI0907371A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
BRPI0907371A 2008-01-09 2009-01-06 derivados de insulina com um perfil de tempo-ação muito retardado BRPI0907371A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE200810003568 DE102008003568A1 (de) 2008-01-09 2008-01-09 Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
US4465908P 2008-04-14 2008-04-14
DE200810025008 DE102008025008A1 (de) 2008-05-24 2008-05-24 Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
PCT/EP2009/000017 WO2009087081A2 (de) 2008-01-09 2009-01-06 Neue insulinderivate mit extrem verzögertem zeit-/wirkungsprofil

Publications (1)

Publication Number Publication Date
BRPI0907371A2 true BRPI0907371A2 (pt) 2015-11-24

Family

ID=40568276

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0907371A BRPI0907371A2 (pt) 2008-01-09 2009-01-06 derivados de insulina com um perfil de tempo-ação muito retardado

Country Status (31)

Country Link
US (1) US9644017B2 (pt)
EP (1) EP2229407B1 (pt)
JP (1) JP5694779B2 (pt)
KR (1) KR20100111682A (pt)
CN (1) CN102007143B (pt)
AR (1) AR070118A1 (pt)
AU (1) AU2009203809B2 (pt)
BR (1) BRPI0907371A2 (pt)
CA (1) CA2711749A1 (pt)
CL (1) CL2009000017A1 (pt)
CO (1) CO6311108A2 (pt)
DK (1) DK2229407T3 (pt)
DO (1) DOP2010000209A (pt)
EC (1) ECSP10010333A (pt)
ES (1) ES2613152T3 (pt)
GT (1) GT201000199A (pt)
HU (1) HUE030537T2 (pt)
IL (1) IL206844A (pt)
MA (1) MA31998B1 (pt)
MY (1) MY152979A (pt)
NI (1) NI201000114A (pt)
NZ (1) NZ586590A (pt)
PA (1) PA8811601A1 (pt)
PE (1) PE20091377A1 (pt)
PL (1) PL2229407T3 (pt)
RU (1) RU2524423C2 (pt)
TN (1) TN2010000298A1 (pt)
TW (1) TW200942256A (pt)
UY (1) UY31596A1 (pt)
WO (1) WO2009087081A2 (pt)
ZA (1) ZA201003926B (pt)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005046113A1 (de) * 2005-09-27 2007-03-29 Sanofi-Aventis Deutschland Gmbh Verfahren zur Amidierung von Polypetiden mit C-terminalen basischen Aminosäuren unter Verwendung spezifischer Endoproteasen
US8343914B2 (en) 2006-01-06 2013-01-01 Case Western Reserve University Fibrillation resistant proteins
EP2074140B8 (en) 2006-10-04 2015-10-28 Case Western Reserve University Fibrillation-resistant insulin and insulin analogues
KR20100111683A (ko) 2008-01-09 2010-10-15 사노피-아벤티스 도이칠란트 게엠베하 극히 지연된 시간-작용 프로필을 갖는 신규 인슐린 유도체
RU2524423C2 (ru) 2008-01-09 2014-07-27 Санофи-Авентис Дойчланд Гмбх Новые производные инсулина с чрезвычайно замедленным профилем время/действие
WO2009129250A2 (en) 2008-04-14 2009-10-22 Case Western Reserve University Meal-time insulin analogues of enhanced stability
AU2009240636A1 (en) * 2008-04-22 2009-10-29 Case Western Reserve University Isoform-specific insulin analogues
US9200053B2 (en) 2008-07-31 2015-12-01 Case Western Reserve University Insulin analogues containing penta-fluoro-Phenylalanine at position B24
KR20120129875A (ko) 2008-07-31 2012-11-28 케이스 웨스턴 리저브 유니버시티 염소화 아미노산을 갖는 인슐린 유사체
PT3228320T (pt) 2008-10-17 2020-03-26 Sanofi Aventis Deutschland Combinação de uma insulina e de um agonista do glp-1
US8642540B2 (en) 2008-12-15 2014-02-04 Zealand Pharma A/S Glucagon analogues
ES2502218T3 (es) 2008-12-15 2014-10-03 Zealand Pharma A/S Análogos de glucagón
MA32970B1 (fr) 2008-12-15 2012-01-02 Zealand Pharma As Analogues du glucagon
AU2008365557A1 (en) 2008-12-15 2011-07-21 Zealand Pharma A/S Glucagon analogues
PH12011502708B1 (en) * 2009-07-06 2017-11-10 Sanofi Aventis Deutschland Insulin preparations containing methionine
EP2451471A1 (de) * 2009-07-06 2012-05-16 Sanofi-Aventis Deutschland GmbH Langsamwirkende insulinzubereitungen
WO2011003820A1 (de) * 2009-07-06 2011-01-13 Sanofi-Aventis Deutschland Gmbh Hitze- und schüttelstabile insulinzubereitungen
JP6054742B2 (ja) 2009-07-13 2016-12-27 ジーランド ファーマ アクティーゼルスカブ アシル化グルカゴン類似体
US8399407B2 (en) 2009-09-17 2013-03-19 Case Western Reserve University Non-standard insulin analogues
SG10201500871TA (en) 2009-11-13 2015-04-29 Sanofi Aventis Deutschland Pharmaceutical composition comprising a glp-1 agonist and methionine
JP5832439B2 (ja) * 2009-11-13 2015-12-16 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Ｇｌｐ−１アゴニスト、インスリン及びメチオニンを含む薬学的組成物
RU2012123642A (ru) 2009-12-11 2014-01-20 Кейз Вестерн Ризев Юнивесити Аналоги инсулина, содержащие хлорированные аминокислоты
EP2585483A1 (en) 2010-06-23 2013-05-01 Novo Nordisk A/S Human insulin containing additional disulfide bonds
CA2802510A1 (en) 2010-06-23 2011-12-29 Novo Nordisk A/S Insulin derivatives containing additional disulfide bonds
AR081975A1 (es) 2010-06-23 2012-10-31 Zealand Pharma As Analogos de glucagon
PH12012502524A1 (en) 2010-06-24 2014-02-10 Boehringer Ingelheim Int Diabetes therapy
CA2802897A1 (en) 2010-06-24 2011-12-29 Zealand Pharma A/S Glucagon analogues
CN103179978A (zh) 2010-08-30 2013-06-26 赛诺菲-安万特德国有限公司 Ave0010用于制造供治疗2型糖尿病用的药物的用途
US20120283169A1 (en) 2010-11-08 2012-11-08 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
EA201390796A1 (ru) 2011-01-20 2014-07-30 Зилэнд Фарма А/С Применение ацилированного аналога глюкагона
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
UA113626C2 (xx) * 2011-06-02 2017-02-27 Композиція для лікування діабету, що містить кон'югат інсуліну тривалої дії та кон'югат інсулінотропного пептиду тривалої дії
JP6367115B2 (ja) 2011-08-29 2018-08-01 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング ２型糖尿病患者の血糖コントロールに使用する組合せ医薬
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
WO2013059213A1 (en) * 2011-10-18 2013-04-25 Amidebio, Llc Chemically and thermodynamically stable insulin analogues and improved methods for their production
CA2872314C (en) 2012-05-03 2021-08-31 Zealand Pharma A/S Gip-glp-1 dual agonist compounds and methods
NZ704043A (en) 2012-07-23 2017-07-28 Zealand Pharma As Glucagon analogues
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
HUE035803T2 (en) 2012-12-21 2018-05-28 Sanofi Sa Dual GLP1 / GIP or trigonal GLP1 / GIP / glucagon agonists
TWI780236B (zh) 2013-02-04 2022-10-11 法商賽諾菲公司 胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物
US9163073B2 (en) 2013-04-17 2015-10-20 Amidebio, Llc Chemically and thermodynamically stable insulin analogues and improved methods for their production
AR098065A1 (es) 2013-10-17 2016-04-27 Zealand Pharma As Análogos de glucagón acilados
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
AU2014345570B2 (en) 2013-11-06 2019-01-24 Zealand Pharma A/S Glucagon-GLP-1-GIP triple agonist compounds
CA2929459C (en) 2013-11-06 2022-05-03 Zealand Pharma A/S Gip-glp-1 dual agonist compounds and methods
CA2932873A1 (en) 2014-01-09 2015-07-16 Sanofi Stabilized pharmaceutical formulations of insulin aspart
KR20160104726A (ko) 2014-01-09 2016-09-05 사노피 인슐린 유사체 및/또는 인슐린 유도체의 안정화된 무글리세롤 약제학적 제형
JP6641280B2 (ja) 2014-01-09 2020-02-05 サノフイＳａｎｏｆｉ インスリンアナログおよび／またはインスリン誘導体の安定化された医薬製剤
MY186251A (en) 2014-01-20 2021-06-30 Hanmi Pharm Ind Co Ltd Long-acting insulin and use thereof
AR100639A1 (es) 2014-05-29 2016-10-19 Hanmi Pharm Ind Co Ltd Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada
TWI684458B (zh) 2014-05-30 2020-02-11 南韓商韓美藥品股份有限公司 包含胰島素及ｇｌｐ-１/昇糖素雙重促效劑之治療糖尿病之組成物
AU2015328222B9 (en) 2014-10-06 2020-12-24 Case Western Reserve University Biphasic single-chain insulin analogues
EP3212218B1 (en) 2014-10-29 2021-06-30 Zealand Pharma A/S Gip agonist compounds and methods
CN107206058A (zh) 2014-12-12 2017-09-26 赛诺菲-安万特德国有限公司 甘精胰岛素/利西拉来固定比率配制剂
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
PL3283507T3 (pl) 2015-04-16 2020-05-18 Zealand Pharma A/S Acylowany analog glukagonu
UY36870A (es) 2015-08-28 2017-03-31 Hanmi Pharm Ind Co Ltd Análogos de insulina novedosos
AU2017332408B2 (en) 2016-09-23 2022-02-10 Hanmi Pharm. Co., Ltd. Insulin analogs with reduced affinity to insulin receptor and use thereof
WO2018174668A2 (ko) 2017-03-23 2018-09-27 한미약품 주식회사 인슐린 수용체와의 결합력이 감소된 인슐린 아날로그의 결합체 및 이의 용도

Family Cites Families (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3984696A (en) 1974-12-11 1976-10-05 Medi-Ray, Inc. Radiation guard for X-ray table
JPS6033474B2 (ja) 1978-05-11 1985-08-02 藤沢薬品工業株式会社 新規なヒアルロニダ−ゼｂｍｐ−８２３１およびその製造法
DK113585D0 (da) 1985-03-12 1985-03-12 Novo Industri As Nye peptider
DK347086D0 (da) * 1986-07-21 1986-07-21 Novo Industri As Novel peptides
US5008241A (en) * 1985-03-12 1991-04-16 Novo Nordisk A/S Novel insulin peptides
PH25772A (en) 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
ES2053723T3 (es) 1987-02-25 1994-08-01 Novo Nordisk As Nuevos derivados de insulina.
DK257988D0 (da) 1988-05-11 1988-05-11 Novo Industri As Nye peptider
US4923162A (en) 1988-09-19 1990-05-08 Fleming Matthew C Radiation shield swivel mount
DE3837825A1 (de) * 1988-11-08 1990-05-10 Hoechst Ag Neue insulinderivate, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung
US5225323A (en) * 1988-11-21 1993-07-06 Baylor College Of Medicine Human high-affinity neurotransmitter uptake system
HUT56857A (en) 1988-12-23 1991-10-28 Novo Nordisk As Human insulin analogues
IL93282A (en) 1989-02-09 1995-08-31 Lilly Co Eli Insulin analogues
DK134189D0 (da) 1989-03-20 1989-03-20 Nordisk Gentofte Insulinforbindelser
US5006718A (en) 1989-07-21 1991-04-09 Lenhart Mark J X-ray shield for X-ray examination table
IL95495A (en) 1989-08-29 1996-10-16 Hoechst Ag Fusion proteins their preparation and use
DK155690D0 (da) 1990-06-28 1990-06-28 Novo Nordisk As Nye peptider
DK10191D0 (da) * 1991-01-22 1991-01-22 Novo Nordisk As Hidtil ukendte peptider
US5358708A (en) 1993-01-29 1994-10-25 Schering Corporation Stabilization of protein formulations
DE4405388A1 (de) 1994-02-19 1995-08-24 Hoechst Ag Verfahren zur Herstellung von Polyalkyl-1-oxa-diazaspirodecan-Verbindungen
AR002976A1 (es) 1995-03-31 1998-05-27 Lilly Co Eli Formulaciones farmaceuticas parenterales de efecto prolongado de insulina; cristales de dichos analogos aplicables en dichas formulaciones yprocedimiento de las formulaciones mencionadas
IL118127A0 (en) 1995-05-05 1996-09-12 Lilly Co Eli Single chain insulin with high bioactivity
JPH11292787A (ja) 1995-08-15 1999-10-26 Asahi Chem Ind Co Ltd 生理活性ペプチドを含有する経粘膜投与製剤
DE19637230A1 (de) 1996-09-13 1998-03-19 Boehringer Mannheim Gmbh Exendin-Analoga, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel
CA2258099A1 (en) 1996-06-20 1997-12-24 Novo Nordisk A/S Insulin preparations containing carbohydrates
DE122009000079I2 (de) 1996-08-30 2011-06-16 Novo Nordisk As Novo Alle Glp-1 derivate
US7312196B2 (en) 1997-01-08 2007-12-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
DE19726167B4 (de) 1997-06-20 2008-01-24 Sanofi-Aventis Deutschland Gmbh Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung
DE19735711C2 (de) 1997-08-18 2001-04-26 Aventis Pharma Gmbh Verfahren zur Herstellung eines Vorläufers von Insulin oder Insulinderivaten mit korrekt verbundenen Cystinbrücken
HUP0004169A3 (en) 1997-10-24 2001-06-28 Lilly Co Eli Insoluble insulin compositions and process for production thereof
US6444641B1 (en) * 1997-10-24 2002-09-03 Eli Lilly Company Fatty acid-acylated insulin analogs
US5981964A (en) 1997-12-22 1999-11-09 Bruce J. McAuley Adjustable X-ray shield and on-line dosimetry system using same
DE69924232D1 (de) 1998-01-09 2005-04-21 Novo Nordisk As Stabilisierte insulin-zubereitungen
CN1241942C (zh) 1998-02-23 2006-02-15 纽罗克里恩生物科学有限公司 使用胰岛素的肽类似物治疗糖尿病的方法
DE69939900D1 (de) 1998-06-05 2008-12-24 Nutrinia Ltd Insulin angereichertes säuglingsnährpräparat
JP2007204498A (ja) 1999-03-01 2007-08-16 Chugai Pharmaceut Co Ltd 長期安定化製剤
JP2000247903A (ja) 1999-03-01 2000-09-12 Chugai Pharmaceut Co Ltd 長期安定化製剤
EP1076066A1 (en) 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides for lowering blood glucose levels
DE19947456A1 (de) * 1999-10-02 2001-04-05 Aventis Pharma Gmbh C-Peptid zur verbesserten Herstellung von Insulin und Insulinanaloga
CZ305123B6 (cs) 1999-10-04 2015-05-13 Novartis Vaccines And Diagnostics, Inc. Způsob výroby kapalného farmaceutického prostředku
US7060675B2 (en) 2001-02-15 2006-06-13 Nobex Corporation Methods of treating diabetes mellitus
DE10108211A1 (de) 2001-02-20 2002-08-22 Aventis Pharma Gmbh Verwendung von Fusionsproteinen, deren N-terminaler Anteil aus einem Hirudinderivat besteht, zur Herstellung rekombinanter Proteine über Sekretion durch Hefen
DE10108212A1 (de) 2001-02-20 2002-08-22 Aventis Pharma Gmbh Fusionsprotein zur Sekretion von Wertprotein in bakterielle Überstände
WO2002067969A2 (en) 2001-02-21 2002-09-06 Medtronic Minimed, Inc. Stabilized insulin formulations
DE10114178A1 (de) 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
EP1377608B1 (en) * 2001-04-02 2009-09-16 Novo Nordisk A/S Insulin precursors and a process for their preparation
WO2003020201A2 (en) 2001-08-28 2003-03-13 Eli Lilly And Company Pre-mixes of glp-1 and basal insulin
AU2002346490A1 (en) 2001-12-20 2003-07-09 Eli Lilly And Company Insulin molecule having protracted time action
JP2005530683A (ja) 2001-12-21 2005-10-13 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 第ｖｉｉ因子ポリペプチドの液体組成物
US8058233B2 (en) 2002-01-10 2011-11-15 Oregon Health And Science University Modification of feeding behavior using PYY and GLP-1
DE10227232A1 (de) 2002-06-18 2004-01-15 Aventis Pharma Deutschland Gmbh Saure Insulinzubereitungen mit verbesserter Stabilität
MXPA04012497A (es) 2002-07-04 2005-07-14 Zealand Pharma As Glp-1 y metodos para tratar la diabetes.
BR0314996A (pt) 2002-10-02 2005-08-09 Zealand Pharma As Composição, composição farmaceuticamente aceitável, método para produzir a composição, métodos para estabilizar a exendina-4 (1-39) ou uma sua variante, derivado ou análogo contra a degradação, antes, durante ou após o uso pretendido, para tratar doenças, para tratar de estados de doenças associados com nìveis elevados de glicose do sangue, para a regulação dos nìveis de glicose do sangue, para a regulação do esvaziamento gástrico, para estimular a liberação de insulina em um mamìfero para reduzir o nìvel de glicose do sangue em um mamìfero, para reduzir o nìvel de lipìdeos plasmáticos em um mamìfero, para reduzir a mortalidade e a morbidez após o infarto miocárdico em um mamìfero, para estimular a liberação de insulina em um mamìfero, e para produzir uma exendina (1-39) estabilizada, e, exendina (1-39) estabilizada
WO2004096854A2 (en) 2003-04-29 2004-11-11 Eli Lilly And Company Insulin analogs having protracted time action
DE10325567B4 (de) 2003-06-05 2008-03-13 Mavig Gmbh Strahlenschutzanordnung mit separierbarer Umhüllung
JP4800959B2 (ja) 2003-11-13 2011-10-26 ノヴォ ノルディスク アー／エス 糖尿病及び過食症を治療するためのｇｌｐ−１ペプチド及び短時間作用型インスリンペプチドを含む、非経口投与用の可溶性医薬組成物
US20080248999A1 (en) 2007-04-04 2008-10-09 Biodel Inc. Amylin formulations
US20080090753A1 (en) 2004-03-12 2008-04-17 Biodel, Inc. Rapid Acting Injectable Insulin Compositions
JP2008507280A (ja) 2004-07-21 2008-03-13 アンブレツクス・インコーポレイテツド 非天然コードアミノ酸を用いた生合成ポリペプチド
US20080280814A1 (en) 2004-09-17 2008-11-13 Novo Nordisk A/S Pharmaceutical Compositions Containing Insulin and Insulinotropic Peptide
DE102004058306A1 (de) 2004-12-01 2006-07-27 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung von Carboxy-terminal amidierten Peptiden
US20090142338A1 (en) 2005-03-04 2009-06-04 Curedm, Inc. Methods and Compositions for Treating Type 1 and Type 2 Diabetes Mellitus and Related Conditions
ATE517919T1 (de) 2005-09-14 2011-08-15 Sanofi Aventis Deutschland Spaltung von insulinvorstufen durch eine trypsinvariante
KR101105871B1 (ko) 2005-09-27 2012-01-16 주식회사 엘지생명과학 인 난포자극호르몬의 안정한 용액 제형
US8343914B2 (en) * 2006-01-06 2013-01-01 Case Western Reserve University Fibrillation resistant proteins
CN101371586B (zh) 2006-01-10 2012-06-27 汤姆森特许公司 用于并行实现4:4:4编码的方法和装置
US20070191271A1 (en) 2006-02-10 2007-08-16 Dow Pharmaceutical Sciences Method for stabilizing polypeptides lacking methionine
WO2007095288A2 (en) 2006-02-13 2007-08-23 Nektar Therapeutics Methionine-containing protein or peptide compositions and methods of making and using
US7763582B2 (en) 2006-02-21 2010-07-27 University Of Medicine And Dentistry Of New Jersey Localized insulin delivery for bone healing
TW200806317A (en) 2006-03-20 2008-02-01 Wyeth Corp Methods for reducing protein aggregation
DE102006031962A1 (de) 2006-07-11 2008-01-17 Sanofi-Aventis Deutschland Gmbh Amidiertes Insulin Glargin
CN101541830A (zh) 2006-09-22 2009-09-23 诺沃-诺迪斯克有限公司 蛋白酶抗性的胰岛素类似物
EP2157967B1 (en) 2007-04-23 2013-01-16 Intarcia Therapeutics, Inc Suspension formulations of insulinotropic peptides and uses thereof
WO2008145323A1 (en) 2007-05-31 2008-12-04 F. Hoffmann-La Roche Ag Pharmaceutical formulation for interferons
DK2173407T3 (da) 2007-07-02 2020-04-27 Hoffmann La Roche Anordning til indgivelse af lægemiddel
ES2393233T3 (es) 2007-11-01 2012-12-19 Merck Serono S.A. Formulaciones de LH líquidas
ES2543393T3 (es) 2007-11-08 2015-08-18 Novo Nordisk A/S Derivado de insulina
RU2524423C2 (ru) 2008-01-09 2014-07-27 Санофи-Авентис Дойчланд Гмбх Новые производные инсулина с чрезвычайно замедленным профилем время/действие
KR20100111683A (ko) 2008-01-09 2010-10-15 사노피-아벤티스 도이칠란트 게엠베하 극히 지연된 시간-작용 프로필을 갖는 신규 인슐린 유도체
TWI394580B (zh) 2008-04-28 2013-05-01 Halozyme Inc 超快起作用胰島素組成物
PT3228320T (pt) 2008-10-17 2020-03-26 Sanofi Aventis Deutschland Combinação de uma insulina e de um agonista do glp-1
JP2009091363A (ja) 2008-11-21 2009-04-30 Asahi Kasei Pharma Kk Ｐｔｈの安定化水溶液注射剤
EP2451471A1 (de) 2009-07-06 2012-05-16 Sanofi-Aventis Deutschland GmbH Langsamwirkende insulinzubereitungen
WO2011003820A1 (de) 2009-07-06 2011-01-13 Sanofi-Aventis Deutschland Gmbh Hitze- und schüttelstabile insulinzubereitungen
PH12011502708B1 (en) 2009-07-06 2017-11-10 Sanofi Aventis Deutschland Insulin preparations containing methionine
JP5832439B2 (ja) 2009-11-13 2015-12-16 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Ｇｌｐ−１アゴニスト、インスリン及びメチオニンを含む薬学的組成物
SG10201500871TA (en) 2009-11-13 2015-04-29 Sanofi Aventis Deutschland Pharmaceutical composition comprising a glp-1 agonist and methionine
AU2011202239C1 (en) 2010-05-19 2017-03-16 Sanofi Long-acting formulations of insulins
GB201303771D0 (en) 2013-03-04 2013-04-17 Midatech Ltd Nanoparticles peptide compositions
TW201605489A (zh) 2013-10-25 2016-02-16 賽諾菲公司 賴谷胰島素（ｉｎｓｕｌｉｎ ｇｌｕｌｉｓｉｎｅ）的穩定調配物

Also Published As

Publication number Publication date
HK1149772A1 (zh) 2011-10-14
MA31998B1 (fr) 2011-01-03
DOP2010000209A (es) 2010-08-31
TN2010000298A1 (en) 2011-11-11
JP2011509088A (ja) 2011-03-24
US9644017B2 (en) 2017-05-09
MY152979A (en) 2014-12-15
UY31596A1 (es) 2009-08-31
WO2009087081A2 (de) 2009-07-16
KR20100111682A (ko) 2010-10-15
PE20091377A1 (es) 2009-09-26
CN102007143B (zh) 2015-08-26
US20110077197A1 (en) 2011-03-31
ES2613152T3 (es) 2017-05-22
TW200942256A (en) 2009-10-16
EP2229407B1 (de) 2016-11-16
ECSP10010333A (es) 2010-08-31
CN102007143A (zh) 2011-04-06
CA2711749A1 (en) 2009-07-16
ZA201003926B (en) 2011-04-28
AU2009203809A1 (en) 2009-07-16
CO6311108A2 (es) 2011-08-22
AU2009203809B2 (en) 2013-07-25
WO2009087081A3 (de) 2009-09-17
AR070118A1 (es) 2010-03-17
JP5694779B2 (ja) 2015-04-01
PA8811601A1 (es) 2009-08-26
NI201000114A (es) 2011-03-15
IL206844A0 (en) 2010-12-30
GT201000199A (es) 2013-11-18
RU2524423C2 (ru) 2014-07-27
NZ586590A (en) 2012-06-29
DK2229407T3 (en) 2017-02-27
EP2229407A2 (de) 2010-09-22
HUE030537T2 (en) 2017-05-29
RU2010133231A (ru) 2012-02-20
IL206844A (en) 2016-02-29
CL2009000017A1 (es) 2009-10-23
PL2229407T3 (pl) 2017-06-30

Similar Documents

Publication Publication Date Title
NO2024044I1 (no) Insulin icodec
IL206844A (en) Insulin derivatives with a highly delayed action profile
IL206843A0 (en) Novel insulin derivatives having an extremely delayed time-action profile
DK2308877T3 (da) Imidazopyridin-2-on-derivater
BRPI0923868A2 (pt) transparência com sensores
BRPI0919155A2 (pt) composição aquosa injetável
BRPI0911782A2 (pt) composição de insulina de ação super rápida
BRPI0915064A2 (pt) derivados de qunoxalinadiona
DK2366113T3 (da) Dgnss-korrektion til positionering
DK2134708T3 (da) 3-Cyano-4-(4-tetrahydropyranphenyl)-pyridin-2-on-derivater
IT1393131B1 (it) Controvento a ingobbamento limitato
DK2245130T3 (da) Ts23 -alpha-amylasevarianter med ændrede egenskaber
BRPI0907435A2 (pt) Derivados de 5-flúor pirimidina
EP2379160A4 (en) MAKING A PLASTER
BRPI0907755A2 (pt) Artigo multimarcas
BRPI0913832A2 (pt) derivados de pirrolopiridinilpirimidin-2-ilamina
BRPI1012770A2 (pt) derivados de tiofeno
GB0812031D0 (en) Thiazole derivatives
BRPI0918823A2 (pt) beta-glicosidases modificadas com estabilidades aperfeicoada
FI20085199A0 (fi) Esikammiojärjestely
DK2275414T3 (da) Cyclopentylacrylamidderivat
DK2254637T3 (da) Kateter
DK2318378T3 (da) Quinazolin-derivater
BRPI0906357A2 (pt) Derivados de oxazepinopirimidona arilamida substituídos
BRPI0922652A2 (pt) Derivados de quinazolinamida

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2384 DE 13-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.